| 摘要 |
Methods for the diagnosis of lung cancer and more specifically, non-small cell lung cancer are described. An assortment of biomarkers with diagnostic or prognostic value for non-small cell lung cancer (NSCLC) have been identified to establish a multi-analyte serum test capable of diagnosing patients with lung cancer. A first method determines whether or not a patient has lung cancer by assessing an elevated level of expression of one or more nucleic acids, or a polypeptide encoded by the nucleic acid or an autoantibody to said polypeptide, selected from the group consisting of TNF-α, CYFRA 21.1, IL-lra, IL-6, IFN-γ, IL-2Rα, CA125, MCP-1, CRP, MMP-2 and sE-selectin where the presence or absence of the elevated level indicates that the patient has NSCLC. In an alternate assay, the method comprises (a) determining whether or not a patient has NSCLC versus a non-NSCLC lung cancer, and (b) classifying the patient as susceptible to specific treatments if the patient has a NSCLC profile and classifying the patient as not susceptible to a specific treatment if the patient does not have a NSCLC profile by determining an elevated level of expression of one or more nucleic acids, or a polypeptide encoded by the nucleic acid or an autoantibody to said polypeptide, selected from the group consisting of inosine-5-monophosphate dehydrogenase (IMPDH), fumarate hydratase (FH), α-enolase, endoplasmic reticulum protein 29 (Erp29), annexin I, hydrosteroid 17-&bgr; dehydrogenase, methylthioadenosine phosphorylase (MTAP), annexin II, ubiquilin, c-Myc, NY-ESO, 3-oxoacid CoA transferase, p53 phosphoglycerate mutase, and heat shock protein 70-9B (HSP70-9B)]. |
